Glaxosmithkline Biologicals Sa

Silvana Savino

Mariagrazia Pizza

Maria Scarselli

Maurizio Comanducci

Brunella Brunelli

Guido Grandi

Fabio Bagnoli

Maria Aricò

Michele Pallaoro

Fabiana Falugi

Massimo Mariani

Mikkel Nissum

Beatrice Maria Arico

The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. The compositions are adjuvanted with an aluminium phosphate adjuvant.

Adjuvanted combinations of meningococcal factor H binding proteins

The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence.

Combinations of meningococcal factor H binding proteins

Elimination of disulphide bond formation of cysteine-containingantigens enhances antigen stability. The invention provides variant forms of cysteine-containingantigen with a point mutation that replaces, deletes or modifies the cysteine residue.

[object Object]

Growing community of inventors

Tavarnelle Val di Pesa, Italy

Silvana Savino